Leonard J P, Neben T Y, Kozitza M K, Quinto C M, Goldman S J
Preclinical Biology, Genetics Institute, Cambridge, MA 02140, USA.
Exp Hematol. 1996 Feb;24(2):270-6.
Previous studies have shown that subcutaneous (SC) bolus administration of recombinant human interleukin-11 (rhIL-11) stimulates megakaryocytopoiesis and increases peripheral platelet counts in naive mice. This study was designed to determine whether administration of rhIL-11 by constant SC infusion altered either the magnitude of the nature of the hematologic response. Female C57BL/6 mice were implanted subcutaneously with 7-day Alzet mini-osmotic pumps containing either rhIL-11 with 0.5% homologous mouse serum (delivery rate of 250 microg/kg/d) or vehicle alone. Mice were sacrificed on days 3, 7, 10, and 13 after pump implantation, and the hematopoietic response was compared to mice receiving an equivalent dose of rhIL-11 administered by SC injection (250 microg/kg/d, 7 days) or vehicle controls. Subcutaneous injection of rhIL-11 resulted in a significant increase in peripheral platelet counts with a maximum platelet increase of 44% over controls observed on day 7 of the study. Platelet counts subsequently declined (24% by day 10) returning to control values by day 13. The increase in peripheral platelet counts was accompanied by an increase in reticulated platelets on day 7 and a shift to higher ploidy bone marrow megakaryocytes on days 3 and 7. Compared to SC injection, both the magnitude and duration of the platelet increase were significantly enhanced following continuous SC infusion of rhIL-11. Maximum platelet counts were detected on day 10 (115% above vehicle controls), and platelets remained significantly elevated on day 13 (84%), 6 days after rhIL-11 administration had stopped. Consistent with the platelet response, the modal ploidy of bone marrow megakaryocytes was shifted from 16N to 32N on days 3 and 7, with increases in 32N megakaryocytes still apparent on days 10 and 13. There was also a significant increase in reticulated platelets detected in the peripheral blood on days 3, 7, and 10 compared to mice administered rhIL-11 by SC injection, The changes in reticulated platelets and bone marrow megakaryocyte ploidy are consistent with the increased and prolonged platelet response following SC infusion of rhIL-11. In addition to the effects observed on peripheral platelet counts, constant SC infusion of rhIL-11 dramatically enhanced splenic hematopoietic activity, increasing spleen weight and cellularity as well as splenic megakaryocyte, erythroid, granulocyte, and macrophage progenitors compared to mice receiving rhIL-11 by SC injection.
先前的研究表明,皮下(SC)推注重组人白细胞介素-11(rhIL-11)可刺激幼稚小鼠的巨核细胞生成并增加外周血小板计数。本研究旨在确定持续皮下输注rhIL-11是否会改变血液学反应的程度或性质。将含有rhIL-11和0.5%同源小鼠血清(给药速率为250μg/kg/d)或仅含赋形剂的7天Alzet微型渗透泵皮下植入雌性C57BL/6小鼠体内。在泵植入后第3、7、10和13天处死小鼠,并将造血反应与接受同等剂量rhIL-11皮下注射(250μg/kg/d,7天)的小鼠或赋形剂对照进行比较。皮下注射rhIL-11导致外周血小板计数显著增加,在研究第7天观察到血小板最大增加量比对照组高44%。随后血小板计数下降(到第10天下降24%),到第13天恢复到对照值。外周血小板计数的增加伴随着第7天网织血小板的增加以及第3天和第7天骨髓巨核细胞向更高倍体的转变。与皮下注射相比,持续皮下输注rhIL-11后血小板增加的幅度和持续时间均显著增强。在第10天检测到最大血小板计数(比赋形剂对照高115%),在rhIL-11给药停止6天后的第13天血小板仍显著升高(84%)。与血小板反应一致,在第3天和第7天骨髓巨核细胞的众数倍体从16N转变为32N,在第10天和第13天32N巨核细胞的增加仍然明显。与皮下注射rhIL-11的小鼠相比,在第3、7和10天在外周血中检测到的网织血小板也显著增加。网织血小板和骨髓巨核细胞倍体的变化与皮下输注rhIL-11后血小板反应的增加和延长一致。除了对外周血小板计数的影响外,与皮下注射rhIL-11的小鼠相比,持续皮下输注rhIL-11显著增强了脾脏造血活性,增加了脾脏重量和细胞数量以及脾脏巨核细胞、红细胞、粒细胞和巨噬细胞祖细胞。